NEW YORK (GenomeWeb) – Sera Prognostics has published an analytical validation study investigating the performance of the company's mass spec assay for the PreTRM test for assessing risk of preterm birth.
NEW YORK (GenomeWeb) – Sera Prognostics has published an analytical validation study investigating the performance of the company's mass spec assay for the PreTRM test for assessing risk of preterm birth.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.